D-cycloserine Augmented CBT for Panic Disorder

University of Oxford

Status and phase: Terminated; Phase 3

Conditions: Panic Disorder

Treatments: Behavioral: cognitive-behaviour therapy; Drug: d-cycloserine; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01680107

MRC-01

2012-003191-39 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to determine whether d-cycloserine augments the clinical effects of exposure-based cognitive-behaviour therapy for panic disorder.

Enrollment: 33 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• clinical diagnosis of panic disorder
• at least moderate agoraphobic avoidance

Exclusion criteria

• psychoactive medication last 6 weeks
• exposure-based cognitive-behaviour treatment for panic disorder and agoraphobia during last 3 months
• female participant who is pregnant or breast-feeding
• lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder
• lifetime history of epilepsy or other significant disease or disorder

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

33 participants in 2 patient groups, including a placebo group

d-cycloserine

Experimental group

Description:

oral, capsule, 250 mg, once

Treatment:

Behavioral: cognitive-behaviour therapy

Drug: d-cycloserine

sugar pill

Placebo Comparator group

Description:

oral, capsule, once

Treatment:

Behavioral: cognitive-behaviour therapy

Drug: placebo